Beta Bionics CCO sells 30,779 company shares

Beta Bionics’ Chief Commercial Officer reported a Rule 10b5-1 planned sale of 30,779 shares, leaving a direct holding of 56,479 shares.

Available on EDGAR 09/17/2026 - 04:16 PM EDT Accepted by SEC EDGAR 09/17/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 30,779 shares of common stock on September 16, 2026. The sale was executed at a weighted average price of $20.1319 per share, in transactions ranging from $20.00 to $20.64, under a Rule 10b5-1 Plan adopted on June 10, 2026. After these sales, Hopman directly holds 56,479 shares of Beta Bionics common stock.

Insider Trade Summary 10b5-1

Net Seller: 30,779 shares

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 30,779 shs ($620K)

Share of Position Sold 35.3%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	30,779	$20.1319	$620K

Holdings After Transaction: Common Stock — 56,479 shares (Direct)

Holdings Before and After: Common Stock, 87,258 to 56,479 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
2. F2. The weighted average sale price for the transaction reported was $20.1319 and the range of prices were between $20.00 and $20.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 30,779 shares Weighted average sale price: $20.1319 per share Shares held after transaction: 56,479 shares +2 more

5 metrics

Shares sold 30,779 shares Common stock sold by Chief Commercial Officer on September 16, 2026

Weighted average sale price $20.1319 per share Average price for the 30,779 shares sold, with a $20.00–$20.64 range

Shares held after transaction 56,479 shares Direct common stock holdings of Mark Hopman following the sale

Rule 10b5-1 Plan adoption date June 10, 2026 Date the trading plan governing the reported sale was adopted

Price range of sales $20.00–$20.64 per share Range of individual transaction prices within the reported sale

Key Terms

Rule 10b5-1 Plan, weighted average sale price, open market or private transaction

3 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $20.1319"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) disclose in this Form 4?

Beta Bionics disclosed that Chief Commercial Officer Mark Hopman sold 30,779 shares of common stock on September 16, 2026, in an open-market or private transaction as reported in the Form 4.

At what price were the 30,779 BBNX shares sold by the Chief Commercial Officer?

The filing reports a weighted average sale price of $20.1319 per share for the 30,779 shares, with individual transaction prices ranging between $20.00 and $20.64 per share.

How many Beta Bionics (BBNX) shares does Mark Hopman hold after this transaction?

After the reported sale, Chief Commercial Officer Mark Hopman directly holds 56,479 shares of Beta Bionics common stock, according to the Form 4.

Was the BBNX insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the shares were sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026, and the document-level Rule 10b5-1 checkbox is also affirmed.

What type of transaction is reported for BBNX in this Form 4?

The Form 4 describes the transaction as a sale of common stock in an open market or private transaction, coded as a non-derivative sale with 30,779 shares disposed of.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		30,779	D	$20.1319(2)	56,479	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.

2. The weighted average sale price for the transaction reported was $20.1319 and the range of prices were between $20.00 and $20.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)